New drug combo tested for Tough-to-Treat bile duct cancer
Disease control
Terminated
This study tested the safety and effectiveness of a new drug called GEN-001 when given alongside an existing immunotherapy (pembrolizumab) for people with advanced bile duct cancer that had stopped responding to standard treatments. It aimed to find the best dose and see if the c…
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated Apr 02, 2026 01:26 UTC